Interaction Checker

Interacciones de Pomalidomida

Pomalidomida (Pomalyst) tiene 29 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 9; moderadas: 20; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (9)

  • Cannabidiol (con receta)anticonvulsivoGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Grave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • FluvoxaminaISRSGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

  • MexiletinaantiarrítmicoGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

  • Viloxazinainhibidor de la recaptación de noradrenalinaGrave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

  • Zileutóninhibidor de CYP1A2Grave

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (etiqueta de Pomalidomida, Interacciones medicamentosas)

Interacciones moderadas (20)

  • ApixabánanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • ArgatrobánanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • BivalirudinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • DabigatránanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • EdoxabánanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • EnoxaparinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Estradiol y dienogestanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • FondaparinuxanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • HeparinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • NoretisteronaprogestágenoModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Noretisterona y etinilestradiolanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • RivaroxabánanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

  • Tabaco y tabaquismoTabaco y cannabisModerada

    Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (etiqueta de Pomalidomida, Advertencias y precauciones)

  • WarfarinaanticoagulanteModerada

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (etiqueta de Pomalidomida, Advertencias y precauciones)

Compruebe Pomalidomida frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.